Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-4.62 Insider Own10.38% Shs Outstand34.94M Perf Week-16.89%
Market Cap12.84M Forward P/E- EPS next Y-2.14 Insider Trans0.00% Shs Float31.32M Perf Month182.77%
Income-40.10M PEG- EPS next Q-0.14 Inst Own2.54% Short Float9.44% Perf Quarter6.18%
Sales0.00M P/S- EPS this Y67.83% Inst Trans-41.00% Short Ratio0.10 Perf Half Y-74.11%
Book/sh-0.48 P/B- EPS next Y-10.88% ROA-90.93% Short Interest2.96M Perf Year-93.21%
Cash/sh0.04 P/C9.59 EPS next 5Y- ROE-322.45% 52W Range0.13 - 5.66 Perf YTD-72.77%
Dividend Est.- P/FCF- EPS past 5Y18.87% ROI- 52W High-93.51% Beta1.86
Dividend TTM- Quick Ratio0.53 Sales past 5Y0.00% Gross Margin- 52W Low186.96% ATR (14)0.08
Dividend Ex-Date- Current Ratio0.53 EPS Y/Y TTM55.02% Oper. Margin0.00% RSI (14)45.38 Volatility7.70% 31.37%
Employees80 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q77.63% Payout- Rel Volume0.07 Prev Close0.40
Sales Surprise- EPS Surprise47.13% Sales Q/Q- EarningsMay 10 Avg Volume29.63M Price0.37
SMA20-27.62% SMA508.21% SMA200-65.08% Trades Volume1,964,286 Change-9.21%
Date Action Analyst Rating Change Price Target Change
May-18-21Initiated BTIG Research Buy $11
Oct-02-20Initiated B. Riley FBR Buy $9
Nov-20-19Initiated Cantor Fitzgerald Overweight $7
Aug-13-19Initiated H.C. Wainwright Buy $7
Jun-21-19Initiated Cantor Fitzgerald Overweight $7
Dec-21-17Initiated Oppenheimer Outperform $18
Jun-28-24 08:00AM
Jun-21-24 04:01PM
Jun-20-24 05:26PM
10:22AM Loading…
Jun-18-24 10:22AM
Jun-17-24 01:28PM
May-22-24 08:04AM
May-16-24 10:53AM
04:01PM Loading…
May-02-24 04:01PM
Apr-30-24 06:03AM
Apr-29-24 08:00PM
Mar-28-24 04:05PM
Mar-11-24 04:05PM
Mar-07-24 07:30AM
Jan-11-24 08:30AM
Dec-11-23 08:30AM
Nov-14-23 04:05PM
Nov-02-23 09:28AM
Oct-30-23 02:15PM
Oct-26-23 12:30PM
Sep-07-23 08:15AM
08:00AM Loading…
Aug-16-23 08:00AM
Aug-14-23 04:05PM
Aug-03-23 08:00AM
Jul-31-23 08:30AM
Jul-06-23 08:00AM
Jun-15-23 04:01PM
Jun-13-23 01:49PM
Jun-12-23 09:55AM
May-26-23 09:55AM
May-18-23 08:03AM
May-15-23 04:01PM
May-12-23 04:05PM
May-11-23 04:03PM
Apr-03-23 12:15PM
Mar-30-23 04:10PM
Mar-29-23 04:15PM
Mar-28-23 08:30AM
Jan-17-23 08:15AM
Dec-19-22 08:30AM
Nov-14-22 04:05PM
Oct-27-22 08:00AM
Oct-06-22 08:30AM
Sep-08-22 08:00AM
Sep-02-22 09:55AM
Aug-11-22 04:05PM
Jul-27-22 08:00AM
Jul-17-22 08:21AM
Jun-22-22 08:00AM
Jun-13-22 08:00AM
May-19-22 03:23PM
May-12-22 04:05PM
May-03-22 08:00AM
Apr-25-22 08:00AM
Apr-21-22 08:30AM
Apr-13-22 10:00AM
Apr-04-22 08:00AM
Apr-01-22 08:30AM
Mar-23-22 04:05PM
Mar-10-22 08:30AM
Mar-09-22 08:00AM
Mar-08-22 09:00AM
Feb-15-22 07:30AM
Feb-08-22 08:30AM
Feb-07-22 09:11AM
Jan-25-22 07:10AM
Jan-24-22 05:00PM
Jan-07-22 02:05PM
Jan-05-22 08:30AM
Dec-16-21 08:30AM
Dec-13-21 09:00AM
Dec-09-21 08:30AM
Dec-06-21 07:30AM
Nov-12-21 08:05AM
Nov-10-21 08:00AM
Nov-09-21 09:02AM
Nov-04-21 09:24AM
Nov-01-21 10:19AM
Oct-06-21 10:28AM
Oct-04-21 09:57AM
Sep-30-21 08:30AM
Sep-28-21 08:30AM
Sep-24-21 06:10AM
Sep-09-21 08:30AM
Aug-16-21 04:01PM
Aug-13-21 10:03AM
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.